Abstract
The rising prevalence of multiresistant Gram-negative bacterial infections has become a major clinical problem, as currently such infections comprise the majority of untreatable bacterial infections. The variety of resistance and transfer mechanisms and their rapid spread among Gram-negative bacteria constitutes a global infection control challenge, and an urgent need for development of new antimicrobials. Unfortunately, infection rates with multiresistant nonfermenters, such as Pseudomonas aeruginosa, Acinetobacter baumannii, or extended-spectrum β-lactamase producing Enterobacteriaceae and carbapenem resistant Enterobacteriaceae such as Klebsiella pneumoniae, are growing progressively while the pace of antibiotic drug development has slowed considerably during the last decade. This chapter reviews the main emerging Gram-negative resistant pathogens, their various resistance mechanisms, prevalence, risk factors, and summarizes the novel drugs being developed against them.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abbo A, Navon-Venezia S, Hammer-Muntz O et al (2005) Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 11:22–29
Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM (2011) Phage treatment of human infections. Bacteriophage 1:66–85
Abraham EP, Chain E (1940) An enzyme from bacteria able to destroy penicillin. Nature 146:837
Aeschlimann JR (2003) The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other Gram-negative bacteria. Pharmacother 23:916–924
Aloush V, Navon-Venezia S, Seigman-Igra Y et al (2006) Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50:43–48
Ambler RP (1980) The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 289:321–331
Anderson DL (2008) Sitafloxacin hydrate for bacterial infections. Drugs Today (Barc) 44:489–501
Arruda EA, Marinho IS, Boulos M et al (1999) Nosocomial infections caused by multiresistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 20:620–623
Baer M, Sawa T, Flynn P et al (2009) An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun 77:1083–1090
Bassetti M, Nicolini L, Esposito S, Righi E, Viscoli C (2009) Current status of newer carbapenems. Curr Med Chem 16:564–575
Beharry Z, Palzkill T (2005) Functional analysis of active site residues of the fosfomycin resistance enzyme FosA from Pseudomonas aeruginosa. J Biol Chem 280:17786–17791
Beno P, Krcmery V, Demitrovicova A (2006) Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin. Clin Microbiol Infect 12:497–498
Bergogne-Berezin E, Towner KJ (1996) Acinetobacter spp. as a nosocomial pathogen: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9:148–165
Bonomo RA, Szabo D (2006) Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 43(Suppl 2):S49–S56
Borer A, Saidel-Odes L, Riesenberg K et al (2009) Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 30:972–976
Bou G, Martinez-Beltran J (2000) Cloning, nucleotide sequencing, and analysis of the gene encoding an AmpC beta-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 44:428–432
Bratu S, Brooks S, Burney S et al (2007) Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 44:972–975
Bratu S, Landman D, Haag R et al (2005) Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City. Arch Intern Med 165:1430–1435
Bush K, Jacoby GA (2010) Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 54:969–976
Bush K, Jacoby GA, Medeiros AA (1995) A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39:1211–1233
Butler MM, Williams JD, Peet NP et al (2010) Comparative in vitro activity profiles of novel bis-indole antibacterials against Gram-positive and Gram-negative clinical isolates. Antimicrob Agents Chemother 54:3974–3977
Buynak JD, Ghadachanda VR, Vogeti L, Zhang H, Chen H (2005) Synthesis and evaluation of 3-(carboxymethylidene)- and 3-(carboxymethyl) penicillinates as inhibitors of beta-lactamase. J Org Chem 70:4510–4513
Canton R, Coque TM (2006) The CTX-M β-lactamase pandemic. Curr Opin Microbiol 9:466–475
CDC (2004) Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002–2004. MMWR Morb Mortal Wkly Rep 53:1063–1066
CDC (2009) Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. Morb Mortal Wkly Rep 58:256–260
Chahine EB, Ferrill MJ, Poulakos MN (2010) Doripenem: a new carbapenem antibiotic. Am J Health Syst Pharm 67:2015–2024
Chang KC, Lin MF, Lin NT, Wu WJ, Kuo HY, Lin TY, Yang TL, Chen YC, Liou ML (2012) Clonal spread of multidrug-resistant Acinetobacter baumannii in eastern Taiwan. J Microbiol Immunol Infect 45:37–42
Curcio D (2011) Activity of a novel combination against multidrug-resistant nonfermenters: ceftazidime plus NXL104. Expert Rev Anti Infect Ther 9:173–176
Da Silva G, Dijkshoorn L, van der Reijden T, van Strijen B, Duarte A (2007) Identification of widespread, closely related Acinetobacter baumannii isolates in Portugal as a subgroup of European clone II. Clin Microbiol Infect 13:190–195
Daikos GL, Karabinis A, Paramythiotou E et al (2007) VIM-1-producing Klebsiella pneumoniae bloodstream infections: analysis of 28 cases. Int J Antimicrob Agents 29:471–473
Datta N (1969) Drug resistance and R factors in the bowel bacteria of London patients before and after admission to hospital. Br Med J 2:407–411
Diekma DJ, Bollet C, Carlioz A et al (2002) Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America SENTRY Antimicrobial Surveillance Program, 1997–2000. Int J Antimicrob Agents 20:412–418
Dozzo P, Moser HE (2008) New aminoglycoside antibiotics. Expert Opin Ther Pat 20:1321–1341
Drlica K, Malik M (2003) Fluoroquinolones: action and resistance. Curr Top Med Chem 3:249–282
Emrich NC, Heisig A, Stubbings W, Labischinski H, Heisig P (2010) Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance. J Antimicrob Chemother 65:2530–2533
Eschenburg S, Priestman M, Schonbrunn E (2005) Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamineenolpyruvyltransferase (MurA) is essential for product release. J Biol Chem 280:3757–3763
European Centre for Disease Prevention and Control (ECDC) (2008) Annual epidemiological report on communicable diseases in Europe 2008. Stockholm, Sweden.http://ecdc.europa.eu/en/publications/Publications/0812_SUR_Annual_Epidemiological_Report_2008.pdf. Accessed March 2012
European Centre for Disease Prevention and Control/European Medicines Agency Joint Working Group (ECDC/EMEA) (2009) The bacterial challenge: time to react. www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf. Accessed March 2012
Falagas ME, Bliziotis IA, Kasiakou SK et al (2005) Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 5:24
Falagas ME, Kopterides P (2006) Risk factors for the isolation of multi-drugresistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 64:7–15
Falagas ME, Rafailidis PI, Kofteridis D, Virtzili D, Chelvatzoglou FC et al (2007) Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 60:1124–1130
Falagas ME, Rafailidis PI, Matthaiou DK (2010) Resistance to polymyxins: mechanisms, frequency and treatment options. Drug Resist Update 13:132–138
Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A (2008) Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 32:450–454
Farrel DJ, Morrissey I, De Rubeis D et al (2003) A UK study of the antimicrobial susceptibility of bacterial pathogen causing urinary tract infection. J Infect 46:94–100
Fluit AC, Verhoef J, Schmitz FJ (2001) European SENTRY participants. frequency of isolation and antimicrobial resistance of Gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997–1998. Eur J Clin Microbiol Infect Dis 20:617–625
Gales AC, Jones RN, Sader HS (2006) Global assessment of the antimicrobial activity of polymyxin B against 54,731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004). Clin Microbiol Infect 12:315–321
Garcia-Penuela E, Aznar E, Alarcon T, Lopez-Brea M (2006) Susceptibility pattern of Acinetobacter baumannii clinical isolates in Madrid vs Hong Kong. Rev Esp Quimioter 19:45–50
Gaynes R, Edwards JR (2005) National nosocomial infections surveillance system. Overview of nococomial infections caused by Gram-negative bacilli. Clin Infect Dis 41:848–854
Georges B, Conil JM, Dubouix A, Archambaud M, Bonnet E, Saivin S et al (2006) Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units. Crit Care Med 34:1636–1641
Giamarellou H, Kanellakopoulou K (2008) Current Therapies for Pseudomonas aeruginosa. Crit Care Clin 24:261–278
Giske CG, Monnet DL, Cars O, Carmeli Y (2008) Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimicrob Agents Chemother 52:813–821
Go ES, Urban C, Burns J, Kreiswirth B et al (1994) Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344:1329–1332
Goa KL, Noble S (2003) Panipenem/betamipron. Drugs 63(9):913–926
Gomi K, Fujimura S, Fuse K et al (2011) Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in the northeastern region of Japan in 2007. J Infect Chemother 17:200–206
Gordon KA, Jones RN; SENTRY participant groups (Europe, Latin America, North America) (2003) Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. results from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 45:295–301
Govan JR, Deretic V (1996) Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60:539–574
Grossman TH, Starosta AL, Fyfe C et al (2012) Target-and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. Feb 21, 2012 (Epub ahead of print)
Hancock RE, Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24:1551–1557
Henrichfreise B, Wiegand I, Pfister W et al (2007) Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother 51:4062–4070
Hirsch EB, Ledesma KR, Chang KT, Motyl MR, Tam VH (2010) In vitro activity of MK-7655 in combination with imipenem (IPM) against carbapenem resistant Gram-negative bacteria. Paper presented at 50th interscience conference on antimicrobial agents and chemotherapy, Boston, MA, USA, 12–15 September 2010
Hornsey M, Ellington MJ, Doumith M et al (2010) AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother 65:1589–1593
Hou J, Huang X, Deng Y, He L et al (2012) Dissemination of fosfomycin resistance gene fosA3 with CTX-M β-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China. Antimicrob Agents Chemother Jan 9 (Epub ahead of print)
Iredell J, Thomas L, Power D, Mendes E (2007) Tigecycline resistance in Australian antibiotic-resistant Gram-negative bacteria. J Antimicrob Chemother 59:816–818
Ishii Y, Eto M, Mano Y, Tateda K, Yamaguchi K (2010) In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase-producing Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 54:3625–3629
Jacoby G, Medeiros A (1991) More extended-spectrum β-lactamases. Antimicrob Agents Chemother 35:1697–1704
Jamieson CE, Lambert PA, Simpson IN (2003) In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother 47:2615–2618
Jia B, Lu P, Huang W et al (2010) A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Chemotherapy 56:285–290
Jones RN, Deshpande L, Fritsche TR, Sader HS (2004) Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999–2003). Diagn Microbiol Infect Dis 49:211–216
Kallel H, Bahloul M, Hergafi L, Akrout M et al (2006) Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 28:366–369
Karlowsky JA, Jones ME, Thornsberry C et al (2003) Trends in antimicrobial susceptibilities among Enterobacteriaceae isolate from hospitalized patients in the United States from 1998 to 2001. Antimicrob Agents Chemother 47:1672–1680
Kaur K, Adediran SA, Lan MJ, Pratt RF (2003) Inhibition of beta-lactamases by monocyclic acyl phosph(on)ates. Biochemistry 42:1529–1536
Keeney D, Ruzin A, Bradford PA (2007) RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb Drug Resist 13:1–6
Keller MA, Stiehm ER (2000) Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 13:602–614
Kitchel B, Rasheed JK, Patel JB et al (2009) Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents and Chemother 53:3365–3370
Klevens RM, Edwards JR, Richards CL et al (2007) Estimating healthcare-associated infections in U.S. hospitals. Public Health Rep 122:160–166
Koga T, Masuda N, Kakuta M, Namba E, Sugihara C, Fukuoka T (2008) Potent In vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 52:2849–2854
Kumarasamy KK, Toleman MA, Walsh TR et al (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10:597–602
Lagacé-Wiens PR, Tailor F, Simner P et al (2011) Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases. Antimicrob Agents Chemother 55:2434–2437
Landman D, Kelly P, Bäcker M et al (2011) Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother 66:332–334
Leavitt A, Navon-Venezia S, Chmelnitsky I et al (2007) Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 51:3026–3029
Lee H, Yong D, Yum JH et al (2006) Dissemination of 16S rRNA methylase-mediated highly amikacin-resistant isolates of Klebsiella pneumoniae and Acinetobacter baumannii in Korea. Diagn Microbiol Infect Dis 56:305–312
Lee HH, Molla MN, Cantor CR, Collins JJ (2010) Bacterial charity work leads to population-wide resistance. Nature 467:82–85
Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG (2009) Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol 47:1611–1612
Livermore DM (2002) Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34:634–640
Livermore DM (2009) Has the era of untreatable infections arrived? J Antimicrob Chemother 64(Suppl 1):i29–i36
Livermore DM, Hope R, Brick G, et al (2008) Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland,2001–06. J Antimicrob Chemother 62(Suppl 2):ii41–ii54
Livermore DM, Mushtaq S, Warner M (2009) Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms. J Antimicrob Chemother 64:330–335
Livermore DM, Mushtaq S, Warner M (2010) Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. J Antimicrob Chemother 65:2382–2395
Livermore DM, Mushtaq S, Warner M, Zhang JC et al (2011) Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 66:48–53
Livermore DM, Woodford N (2006) The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 14:413–420
Lolans KT, Rice W, Munoz-Price LS, Quinn JP (2006) Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 50:2941–2945
MacNeil IA, Tiong CL, Minor C et al (2001) Expression and isolation of antimicrobial small molecules from soil DNA libraries. J Mol Microbiol Biotechnol 3:301–308
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281
Magnet S, Courvalin P, Lambert T (2001) Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 45:3375–3380
Mahgoub S, Ahmed J, Glatt AE (2002) Completely resistant Acinetobacter baumannii strains. Infect Control Hosp Epidemiol 23:477–479
Mansoor UF, Vitharana D, Reddy PA et al (2011) Design and synthesis of potent Gram-negative specific LpxC inhibitors. Bioorg Med Chem Lett 21:1155–1161
Maragakis LL (2010) Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit. Crit Care Med 38(Suppl. 8):S345–S351
Maragakis LL, Perl TM (2008) Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 46:1254–1263
Medina J, Formento C, Pontet J et al (2007) Prospective study of risk factors for ventilator-associated pneumonia caused by Acinetobacter species. J Crit Care 22:18–27
Moland ES, Hanson ND, Black JA et al (2009) Prevalence of newer β-lactamases in Gram-negative clinical isolates collected in the United States from 2001 to 2002. J Clin Microbiol 44:3318–3324
Mortensen NP, Fowlkes JD, Sullivan CJ et al (2009) Effects of colistin on surface ultrastructure and nanomechanics of Pseudomonas aeruginosa cells. Langmuir 25:3728–3733
Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A (2010) Activity of a new cephalosporin, CXA-101 (FR264205), against β-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother 54:1213–1217
Mushtaq S, Warner M, Livermore D (2010) Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters. J Antimicrob Chemother 65:266–270
Naas TS, Kernbaum S, Allali S, Nordmann P (2007) Multidrug-resistant Acinetobacter baumannii, Russia. Emerg Infect Dis 13:669–671
National Institute of Allergy and Infectious Diseases (NIAID) (2006) The problem of antimicrobial resistance. http://www.idph.state.ia.us/adper/common/pdf/abx/tab9_niaid_resistance.pdf. Accessed March 2012
National Nosocomial Infections Surveillance (NNIS) (2004) System report, data summary from January 1992 through June 2004. Am J Infect Control 32:470–485
Navon-Venezia S, Ben-Ami R, Carmeli Y (2005) Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 18:306–313
Nemec A, Dolzani L, Brisse S et al (2004) Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European Acinetobacter baumannii clones. J Med Microbiol 53:1233–1240
Obara M, Nakae T (1991) Mechanisms of resistance to beta-lactam antibiotics in Acinetobacter calcoaceticus. J Antimicrob Chemother 28:791–800
Ohmagari N, Hanna H, Graviss L et al (2005) Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 104:205–212
Oliver A, Canton R, Campo P et al (2000) High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251–1254
Page MG, Dantier C, Desarbre E (2010) In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother 54:2291–2302
Page MG, Dantier C, Desarbre E, Gaucher B et al (2011) In vitro and in vivo properties of BAL30376, a β-lactam and dual beta-lactamase inhibitor combination with enhanced activity against Gram-negative Bacilli that express multiple β-lactamases. Antimicrob Agents Chemother 55:1510–1519
Paramythiotou E, Lucet JC, Timsit JF et al (2004) Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 38:670–677
Patel G, Huprikar S, Factor SH et al (2008) Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 29:1099–1106
Peleg AY, Bell JM, Hofmeyr A, Wiese P (2006) Inter-country transfer of Gram-negative organisms carrying the VIM-4 and OXA-58 carbapenem-hydrolysing enzymes. J Antimicrob Chemother 57:794–795
Peleg AY, Paterson DL (2006) Multidrug-resistant Acinetobacter: a threat to the antibiotic era. Intern Med J 36:479–482
Peleg AY, Seifert H, Paterson DL (2008) Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538–582
Peters BM, Shirtliff ME, Jabra-Rizk MA (2010) Antimicrobial peptides: primeval molecules or future drugs? PLoS Pathog 6(10):e1001067
Peterson LR (2009) Bad bugs, no drugs: no ESCAPE revisited. Clin Infect Dis 49:992–993
Poirel L, Nordmann P (2006) Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 12:826–836
Quale J, Shah N, Kelly P et al (2011) Activity of polymyxin B and the novel polymyxin analogue CB-182, 804 against contemporary Gram-negative pathogens in New York City. Microb Drug Resist, Dec 23, 2011 (Epub ahead of print)
Ribera A, Ruiz J, Vila J (2003) Presence of the Tet M determinant in a clinical isolate of Acinetobacter baumannii. Antimicrob Agents Chemother 47:2310–2312
Rice LB (2006) Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 43(Suppl 2):S100–S105
Rice LB (2008) Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197:1079–1081
Robicsek A, Jacoby GA, Hooper DC (2006) The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 6:629–640
Schneider P, Hawser S, Islam K (2003) Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 13:4217–4221
Schwaber MJ, Carmeli Y (2007) Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and metaanalysis. J Antimicrob Chemother 60:913–920
Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S et al (2008) Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 52:102810–102833
Scott P, Deye G, Srinivasan A, Murray C et al (2007) An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis 44:1577–1584
Seifert H, Stefanik D, Wisplinghoff H (2006) Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 58:1099–1100
Shahid M, Sobia F, Singh A et al (2009) Beta-lactams and beta-lactamase inhibitors in current or potential-clinical practice: a comprehensive update. Crit Rev Microbiol 35:81–108
Shakil S, Khan R, Zarrilli R, Khan AU (2008) Aminoglycosides versus bacteria-a description of the action, resistance mechanism, and nosocomial battleground. J Biomed Sci 15:5–14
Siroy A, Molle V, Lemaitre-Guillier C et al (2005) Channel formation by CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. Antimicrob Agents Chemother 49:4876–4883
Speert DP, Campbell ME, Davidson AG, Wong LT (1993) Pseudomonas aeruginosa colonization of the gastrointestinal tract in patients with cystic fibrosis. J Infect Dis 167:226–229
Spratt BG (1994) Resistance to antibiotics mediated by target alterations. Science 264:388–393
Sutcliffe JA (2011) Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci 1241:122–152
Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K (2007) In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 51:826–830
Talbot GH (2010) The antibiotic development pipeline for multidrug-resistant Gram-negative bacilli: current and future landscapes. Infect Control Hosp Epidemiol 31(Suppl. 1):S55–S58
Tam VH, Kai-Tai Chang KT, Abdelraouf K et al (2010) Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 54:1160–1164
Thomas KD, Adhikari AV, Chowdhury IH et al (2011) Design, synthesis and docking studies of quinoline-oxazolidinone hybrid molecules and their antitubercular properties. Eur J Med Chem 46:4834–4845
Titelman E, Karlsson IM, Ge Y, Giske CG (2011) In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 70:137–141
Török ME, Chapman AL, Lessing MP, Sanderson F, Seaton RA (2010) Outpatient parenteral antimicrobial therapy: recent developments and future prospects. Curr Opin Investig Drugs 11:929–939
Tzouvelekis LS, Gazouli M, Prinarakis EE, Tzelepi E, Legakis NJ (1997) Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone ro 48–1220 against beta-lactamases that belong to groups 1, 2b, and 2be. Antimicrob Agents Chemother 41:475–477
Unal S, Garcia-Rodriguez JA (2005) Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002–2004. Diagn Microbiol Infect Dis 53:265–271
Urbanowski ML, Lykken GL, Yahr TL (2005) A secreted regulatory protein couples transcription to the secretory activity of the Pseudomonas aeruginosa type III secretion system. Proc Natl Acad Sci USA 102:9930–9935
Vaara M, Fox J, Loidl G et al (2008) Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob Agents Chemother 52:3229–3236
Vila J, Ruiz J, Goni P, Jimenez de Anta T (1997) Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother 39:757–762
Vila-Farres X, Garcia de la Maria C, López-Rojas R et al (2012) In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin Microbiol Infect 18:383–387
Wachino J, Yamane K, Suzuki S, Kimura K, Yl Arakawa (2010) Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob Agents Chemother 54:3061–3064
Walther-Rasmussen J, Hoiby N (2007) Class A carbapenemases. J Antimicrob Chemother 60:470–482
Xiao XY, Hunt DK, Zhou J et al (2012) Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem 55:597–605
Yigit H, Queenan AM, Anderson GJ et al (2001) Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45:1151–1161
Yong D, Toleman MA, Giske CG et al (2009) Characterization of a new metallo-β-lactamase gene, bla (NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53:5046–5054
Zavascki AP, Barth AL, Fernandes JF et al (2006) Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-beta-lactamase-mediated multidrug resistance: a prospective observational study. Crit Care 10:R114
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Paitan, Y., Ron, E.Z. (2014). Gram-Negative Pathogens: Overview of Novel and Emerging Resistant Pathogens and Drugs. In: Marinelli, F., Genilloud, O. (eds) Antimicrobials. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39968-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-39968-8_3
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-39967-1
Online ISBN: 978-3-642-39968-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)